electroCore, Inc. (ECOR)
NASDAQ: ECOR · Real-Time Price · USD
5.01
0.00 (0.00%)
Oct 6, 2025, 4:00 PM EDT - Market closed
electroCore Revenue
electroCore had revenue of $7.38M in the quarter ending June 30, 2025, with 20.23% growth. This brings the company's revenue in the last twelve months to $27.70M, up 30.16% year-over-year. In the year 2024, electroCore had annual revenue of $25.18M with 57.09% growth.
Revenue (ttm)
$27.70M
Revenue Growth
+30.16%
P/S Ratio
1.49
Revenue / Employee
$379,452
Employees
73
Market Cap
37.99M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 25.18M | 9.15M | 57.09% |
Dec 31, 2023 | 16.03M | 7.44M | 86.57% |
Dec 31, 2022 | 8.59M | 3.14M | 57.62% |
Dec 31, 2021 | 5.45M | 1.96M | 55.93% |
Dec 31, 2020 | 3.50M | 1.11M | 46.25% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ECOR News
- 3 days ago - electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 days ago - gammaCore® Non-Invasive Vagus Nerve Stimulation (nVNS) as an Adjunctive Treatment Associated with Improvements in Persistent Post-Concussion Symptoms - GlobeNewsWire
- 7 days ago - electroCore Announces Reimbursement Approval for gammaCore™ by RIZIV/INAMI in Belgium - GlobeNewsWire
- 14 days ago - electroCore's Truvaga™ Plus Named “Best Relaxation Gadget” in Esquire's 2025 Sleep Awards - GlobeNewsWire
- 27 days ago - Ecora Resources PLC (ECOR:CA) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - electroCore Announces Departure of Peter Cuneo from the Board of Directors and Elects Thomas J. Errico, MD as Chairman of the Board - GlobeNewsWire
- 4 weeks ago - electroCore Partners with iHeartRadio and Former New York Jets Star Linebacker Greg Buttle to Champion Better Sleep and Stress Relief - GlobeNewsWire
- 4 weeks ago - electroCore Appoints Elena Bonfiglioli to Board of Directors - GlobeNewsWire